济南泌尿科要怎么检查济南哪些药专治阳痿早泄,济南怎样解决龟头过于敏感,济南尿道刺痛有白色分泌物,济南男科医院检查多少钱,济南同房硬不起来可以治吗,济南阳痿早泄能治好啊,济南治阳痿花多少钱

LOS ANGELES, May 15 (Xinhua) -- Using a simple, minimally- invasive technique to analyze cells from the interior of the nose, U.S. researchers have detected lung cancer in its earliest stage.For the study, the researchers at the Boston University Medical Center collected nasal epithelial cells from thirty three smokers who were undergoing medically-indicated bronchoscopies for suspicion of lung cancer, according to the American Association for the Advancement of Science (AAAS) on Sunday.Of these patients, 11 were found to have benign disease and 22 had lung cancer. Brushings were taken from the right or left nostril and profiled on microarrays, a process that allows researchers to study gene expression changes.The researchers identified 170 genes that were differentially expressed between patients with and without lung cancer. They also found that genes linked to colon cancer and adenocarcinoma, as well as genes that trigger cell division and blood vessel growth, were expressed more heavily in patients with cancer. Genes involved in tumor suppression were also expressed at lower levels in these patients.Earlier studies have used gene expression differences in the bronchial airways to identify lung cancer in its early stages. The researchers relied on those results to design the current study."In this study we used the same principle as we used in our earlier studies of bronchial tissue, only this time, those methods were used to study nasal cells," said study author Christina Anderlind, MD, Instructor of Medicine. "Our hypothesis was that the upper airway epithelium of smokers with lung cancer displays a cancer-specific gene expression pattern, and that this airway nasal gene expression signature reflects the changes that occur in lung tissue."

NEW YORK, March 29 (Xinhua) -- New York Attorney General Eric Schneiderman announced on Tuesday that his office will undertake a thorough review of AT&T's acquisition of T-Mobile for potential anti-competitive impacts on consumers and businesses.Schneiderman stressed that his review will weigh the benefits of the merger to New Yorkers, such as expanding the coverage of AT& T's next generation broadband wireless network to rural areas in upstate New York, against the anti-competitive risks posed to them."Cell phones are no longer a luxury for a few among us, but a basic necessity. The last thing New Yorkers need during these difficult economic times is to see cell phone prices rise," said Schneiderman in a statement. "We want to ensure all New Yorkers benefit from these important innovations that improve lives."AT&T's proposed 39-billion-U.S.-dollar purchase of T-Mobile would create the nation's largest wireless company with a total of 130 million subscribers nationwide, opening the door to a near duopoly shared by the merged firm and Verizon, according to the New York Attorney General's office.T-Mobile, a subsidiary of Deutsche Telekom, is a low-cost provider of choice for millions of New Yorkers and currently has 34 million customers nationwide, making it the fourth-largest wireless company in the United States.

CHENGDU, May 8 (Xinhua) -- As a brand-name herbal capsule for cardiovascular disease in China, Di'ao Xinxuekang only needs to wait for another 15 years before reaching the EU market."The Dutch medical supervisors have recognized it as a qualified drug, but we still lack the evidence of 15-year presence in the EU market," said Ji Jianxin, a research manager with the drug's developer Di'ao Group based in southwest China's Sichuan Province.Di'ao, one of the largest Traditional Chinese Medicine (TCM) manufacturers, has been quite depressed, as many other TCM enterprises in China, by a European Union directive on traditional herbal medicinal products fully implemented from the beginning of this month.The directive requires that all herbal medicinal products, must obtain a medical license from any EU member state before it can be allowed in the EU market.It introduced a so-called simplified registration procedure with a seven-year transition period for traditional herbal medicinal products to be licensed, including Chinese and Indian ones.However, not a single Chinese herbal medicinal product has been granted the license so far, mainly due to the prohibitive registration cost and lack of required evidence to prove the product had a 30-year history of safe use, including 15 years in the EU.With a history of more than 2,000 years, TCM did not enter into the EU market until mid-1990s, and it has been imported into the EU and sold to European customers as food supplements instead of drugs.Most Chinese producers and importers did not reserve the customs papers a decade ago, thus unable to prove the 15-year use of their products in European markets.While TCM's globalization won't be doomed by one single EU directive as TCM export value to EU only takes up 14 percent of the total in 2010, experts and industry insiders still have had serious concerns about its future."Most TCM even don't have standardized labels that can help consumers to find out its origin," said Xian Sheng, from the China Association of TCM Export Companies.

TIANJIN, April 16 (Xinhua) -- As China tries to establish a universal medicare umbrella, its first move to offer treatment to all the hemophilia patients in the country is to know their population and where they are.China's national hemophilia information management center registered 7,980 cases nationwide since its establishment last year in a bid to provide reference for making national treatment policies and medicine production quota, said the center officials Saturday.Yang Renchi with the center and the Chinese Academy of Medical Sciences, said that the patient information database will help the government make hemophilia-related medical and social welfare policies, optimize resources and guide the manufacturing of drugs such as coagulation factor VIII.The information center, created by the Ministry of Health, is located in the Blood Diseases Hospital of the Chinese Academy of Medical Sciences in the port city Tianjin in north China.Hemophilia is a rare genetic bleeding disorder that prevents the blood from clotting properly, resulting in easy bruising and prolonged bleeding from trauma. Lack of treatment can lead to permanent disabilities or even death.China is estimated to have roughly 100,000 hemophilia patients."Be inspired; get involved in Treatment for All" is the theme for the 22nd World Hemophilia Day, which falls on Sunday, April 17."A necessary precondition for 'Treatment for All' is to know the clinical information and location of each case," said Yang, "and this is exactly what the information system does."In addition, China plans to establish hospital-based provincial hemophilia management centers within five years across the country to register and monitor patients and standardize disease diagnosis and treatment under the information system.SHORTAGE OF DRUGSBlood-derived coagulation factor VIII and recombinant coagulation factor VIII are two effective drugs which are vital for hemophiliacs. However, the drugs are expensive and produced in limited quantities, a difficulty which hundreds of thousands of hemophiliacs in China have to confront.According to Yang, the minimum dose of coagulation factor VIII for prevention of bleeding episodes is two international units (IU) per kg of weight a day. A 50-kg hemophilia patient needs at least 36,500 IU of factor VIII every year to prevent bleeding."Each IU of blood-derived coagulation factor VIII costs about 3 yuan(0.46 U.S. dollars) and the annual cost is almost 120,000 yuan. The recombinant one is almost twice the price," said Yang.Only four drug firms are qualified to manufacture blood-derived coagulation factor VIII in China. The national output in 2010 was 400,000 vials (200 IU per vial) which means 80 million IU for the entire country.Wu Runhui, a hematology specialist with the Beijing Children's Hospital, said that the minimum dose is only for the prevention of bleeding episodes which are required to keep the patient alive. For the hemophiliac to live a regular lifestyle, 3,000 IU per kilo a year is needed, which would cost half a million yuan a year."Even in the most developed countries, a hemophiliac cannot survive without supportive medical policies and social welfare system," said Wu.

WELLINGTON, May 22 (Xinhua) -- One in every eight women giving birth in a New Zealand hospital last year was Asian, local media reported Sunday.In the country's most populous city, Auckland, 5,149 Asian women gave birth, more than double the number of 15 years ago, the New Zealand Herald reported.Last year was the first year in the city when more Asian women gave birth than indigenous Maori women, who registered 5,015 births.Citing figures from the government statistics agency, Statistics New Zealand, the report said the majority of women nationwide who gave birth last year were still of European descent, accounting for 43,965 of last year's 63,897 births.But more women of other ethnic backgrounds were also becoming mothers, including those from the Middle East, Latin America and Africa.Auckland University head of obstetrics and gynaecology, Professor Lesley McCowan, said the increase reflected New Zealand is an increasingly multicultural society.